Sooin Byeon

Jan 9, 2025 | onlinelibrary.wiley.com | Sooin Byeon |Christopher B. Nahm |John Turchini |Nathalie B. Rasko

FFPE formalin-fixed paraffin-embedded FXYD3 FXYD domain-containing ion transport regulator MAT-8 mammary tumour protein 8 PDAC pancreatic ductal adenocarcinoma TMA tissue microarrays 1 Introduction Pancreatic ductal adenocarcinoma (PDAC) continues to pose a significant clinical challenge with a five-year survival rate of only ~8% and marginal improvements over several decades [1, 2].

Nov 2, 2024 | onlinelibrary.wiley.com | Sooin Byeon |Josef Gillson |Angela Chou |Sarah Maloney

Corresponding Author Anubhav Mittal Northern Clinical School, Faculty of Medicine and Health, University of Sydney, St Leonards, New South Wales, Australia Australian Pancreatic Centre, St Leonards, Sydney, New South Wales, Australia Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, Sydney, New South Wales, Australia The University of Notre Dame Australia, Sydney, New South Wales, Australia Correspondence Sumit Sahni, Northern Clinical School, Kolling...

Mar 22, 2024 | onlinelibrary.wiley.com | Sooin Byeon |Matthew McKay |Biomarker Laboratory |Mark Molloy

1 INTRODUCTION Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest survival rate of all major cancer and is projected to become the second common cause of cancer related death by 2030.1, 2 These dismal statistics are due to many factors, including shortcomings in current management of PDAC. Most PDAC patients have advanced disease at the time of diagnosis. Only 20% of the patients could be offered surgery, the only potentially curative-intent therapy.

Mar 4, 2024 | onlinelibrary.wiley.com | Sooin Byeon |Taymin du Toit-Thompson |Luke Hipperson |Sarah Maloney

1 INTRODUCTION Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and has one of the worst prognostic outcomes (~9% 5-year survival) among all major solid tumors.1 In fact, it is projected to become the second leading cause of cancer-related deaths by 2030.2 The late-stage diagnosis of PDAC is attributable to dismal survival outcomes, as a majority of patients have advanced, unresectable disease at diagnosis.

Aug 3, 2023 | onlinelibrary.wiley.com | Sooin Byeon |Anthony Gill |Taymin du Toit-Thompson |Josef Gillson

3.2 Coexistence of different genotypes within classical biopsy-derived pancreatic cancer organoids Although bulk RNA-sequencing has enabled genotypic classifications of PDAC tumors, this approach may not be adequate to delineate heterogeneous cellular subpopulations in PDAC TME, with growing evidence that more than one genotypic characteristic can be portrayed by different cell types at the single-cell level within a tumor.